Urticaria and angioedema from cyclooxygenase-2 inhibitors
- PMID: 11708434
Urticaria and angioedema from cyclooxygenase-2 inhibitors
Abstract
Cyclooxygenase-2 (COX-2) inhibitors celecoxib and rofecoxib have generally been well tolerated. It has been unclear if specific COX-2 inhibitors would cross react with acetylsalicylic acid and typical nonsteroidal antiinflammatory drugs to cause urticaria or angioedema. There are no reports in the literature of hives or angioedema resulting from their use. We describe 3 patients who developed urticaria and/or angioedema from COX-2 inhibitors. With the increasing use of COX-2 inhibitors, one needs to be aware of these side effects and of possible cross reactivity between celecoxib and rofecoxib.
Similar articles
-
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.Ann Allergy Asthma Immunol. 2005 Jan;94(1):34-8. doi: 10.1016/S1081-1206(10)61282-3. Ann Allergy Asthma Immunol. 2005. PMID: 15702813 Clinical Trial.
-
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.Eur Ann Allergy Clin Immunol. 2004 Jun;36(6):215-8. Eur Ann Allergy Clin Immunol. 2004. PMID: 15329003 Clinical Trial.
-
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.Am J Manag Care. 2002 Oct;8(15 Suppl):S392-400. Am J Manag Care. 2002. PMID: 12416789
-
Angioedema associated with aspirin and rofecoxib.Ann Pharmacother. 2005 May;39(5):944-8. doi: 10.1345/aph.1E546. Epub 2005 Apr 5. Ann Pharmacother. 2005. PMID: 15811906 Review.
-
[COX-2 inhibitors--one step forward and two steps back].Tidsskr Nor Laegeforen. 2005 Apr 7;125(7):875-8. Tidsskr Nor Laegeforen. 2005. PMID: 15815733 Review. Norwegian.
Cited by
-
Risk of hospitalization for angio-oedema among users of newer COX-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs.Br J Clin Pharmacol. 2006 Oct;62(4):496-501. doi: 10.1111/j.1365-2125.2006.02753.x. Epub 2006 Aug 30. Br J Clin Pharmacol. 2006. PMID: 16939524 Free PMC article.
-
COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred.Arthritis Res Ther. 2003;5(3):116-9. doi: 10.1186/ar747. Epub 2003 Feb 27. Arthritis Res Ther. 2003. PMID: 12723976 Free PMC article.
-
COX-2 inhibitors: a CLASS act or Just VIGORously promoted.MedGenMed. 2004 Mar 23;6(1):6. MedGenMed. 2004. PMID: 15208519 Free PMC article. Review.
-
Angioedema without urticaria after recent initiation of celecoxib.BMJ Case Rep. 2023 Sep 22;16(9):e255446. doi: 10.1136/bcr-2023-255446. BMJ Case Rep. 2023. PMID: 37739445
-
Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.Eur J Clin Pharmacol. 2004 Sep;60(7):489-501. doi: 10.1007/s00228-004-0788-2. Eur J Clin Pharmacol. 2004. PMID: 15278327
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials